Temozolomide During and After Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients

Overview

Journal J Korean Neurosurg Soc

Date 2012 Oct 24

PMID 23091665

Citations 7

Authors

Jin-Deok Joo

Jong Hee Chang

Jeong Hoon Kim

Yong-Kil Hong

Young-Hoon Kim

Chae-Yong Kim

Affiliations

Soon will be listed here.

Abstract

Objective: This study was performed to determine the safety and outcome of concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide for Korean patients with a newly diagnosed glioblastoma.

Methods: Patients were recruited from four institutions between 2004 and 2007. The patients received fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks and daily temozolomide, followed by 6 cycles of adjuvant temozolomide. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), response, and safety.

Results: A total of 103 patients were enrolled in this study. Ninety-six patients (93%) completed the CCRT and 54 patients (52%) received 6 cycles of adjuvant temozolomide. The response rate was 73% (53/73) and the tumor control rate was 92% (67/73). Of the 96 patients who completed the CCRT, the median OS was 18.0 months and the 1- and 2-year OS rates were 74 and 38%, respectively. The median PFS was 10.0 months and the 1- and 2-year PFS rates were 33 and 16%, respectively. The only significant prognostic factor of survival was the extent of surgical resection (p<0.05). CCRT resulted in grade 3 or 4 hematologic toxic effects in 8% of patients. No opportunistic infections were noted.

Conclusion: This study is the first prospective multi-institutional report of CCRT and adjuvant chemotherapy with temozolomide for patients with a newly diagnosed glioblastoma in Korea. The current protocol may prolong the survival of Korean patients with a glioblastoma and may be tolerable in terms of toxicity.

Citing Articles

Advancements and challenges in brain cancer therapeutics.

Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.

PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.

Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection.

Kanamori M, Shibahara I, Shimoda Y, Akiyama Y, Beppu T, Ohba S Int J Clin Oncol. 2024; 30(1):51-61.

PMID: 39527165 PMC: 11700082. DOI: 10.1007/s10147-024-02650-9.

Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study.

Hermawan A, Wulandari F, Hanif N, Utomo R, Jenie R, Ikawati M Sci Rep. 2022; 12(1):13928.

PMID: 35977996 PMC: 9385707. DOI: 10.1038/s41598-022-18348-9.

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).

Ahn G, Hwang K, Kim T, Park C, Chang J, Jung T Cancer Res Treat. 2021; 54(2):396-405.

PMID: 34237210 PMC: 9016307. DOI: 10.4143/crt.2021.393.

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.

Kim B, Seol H, Nam D, Park C, Kim I, Kim T Cancer Res Treat. 2016; 49(1):193-203.

PMID: 27384161 PMC: 5266397. DOI: 10.4143/crt.2015.473.

References

Siker M, Chakravarti A, Mehta M . Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Crit Rev Oncol Hematol. 2006; 60(2):99-111. DOI: 10.1016/j.critrevonc.2006.04.005. View

Kim Y, Kim S, Cho J, Kim J, Chang J, Kim D . MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys. 2012; 84(3):661-7. DOI: 10.1016/j.ijrobp.2011.12.086. View

Choi J, Lee M, Kim I, Kim J, Choe G, Kim C . The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc. 2008; 44(4):222-7. PMC: 2588321. DOI: 10.3340/jkns.2008.44.4.222. View

Kim Y, Park C, Cho W, Kim I, Moon S, Choe G . Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. J Neurooncol. 2010; 103(3):503-12. DOI: 10.1007/s11060-010-0404-5. View

DeAngelis L . Brain tumors. N Engl J Med. 2001; 344(2):114-23. DOI: 10.1056/NEJM200101113440207. View

Lakomy R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarova E . [Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009]. Klin Onkol. 2011; 24(2):112-20. View

Song K, Phi J, Cho B, Wang K, Lee J, Kim D . Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr. 2010; 6(2):145-9. DOI: 10.3171/2010.5.PEDS09558. View

Friedman H, McLendon R, Kerby T, Dugan M, Bigner S, HENRY A . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16(12):3851-7. DOI: 10.1200/JCO.1998.16.12.3851. View

Omar A, Mason W . Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid. 2010; 4:93-111. PMC: 2899776. DOI: 10.2147/ce.s6010. View

10.

Stupp R, Dietrich P, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20(5):1375-82. DOI: 10.1200/JCO.2002.20.5.1375. View

11.

Park C, Kim J, Yim S, Lee A, Han J, Kim C . Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol. 2010; 13(2):195-202. PMC: 3064622. DOI: 10.1093/neuonc/noq162. View

12.

Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulera F, Faggionato F . Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol. 2004; 67(1-2):77-81. DOI: 10.1023/b:neon.0000021728.36747.93. View

13.

Jeon H, Kong D, Park K, Lee J, Park K, Kim J . Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg. 2009; 111(8):679-82. DOI: 10.1016/j.clineuro.2009.06.013. View

14.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

15.

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

16.

Kong D, Lee J, Kim J, Kim S, Kim W, Suh Y . Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010; 12(3):289-96. PMC: 2940595. DOI: 10.1093/neuonc/nop030. View

17.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

18.

Ishikawa E, Yamamoto T, Sakamoto N, Nakai K, Akutsu H, Tsuboi K . Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurol Med Chir (Tokyo). 2010; 50(8):638-44. DOI: 10.2176/nmc.50.638. View

19.

Brada M, Hoang-Xuan K, Rampling R, Dietrich P, Dirix L, MacDonald D . Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001; 12(2):259-66. DOI: 10.1023/a:1008382516636. View

20.

Yung W, Albright R, Olson J, Fredericks R, Fink K, PRADOS M . A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83(5):588-93. PMC: 2363506. DOI: 10.1054/bjoc.2000.1316. View